Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-IPV-HB-PRP-T
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP-IPV-HB-PRP-T (marketed under the brand names Hexaxim, Hexyon, Hexacima, and Hexarium) is a fully liquid, ready-to-use hexavalent combination vaccine developed by Sanofi Pasteur. It is indicated for the active immunization of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, hepatitis B, and invasive diseases caused by Haemophilus influenzae type b (Hib). The vaccine contains diphtheria toxoid, tetanus toxoid, two acellular pertussis antigens (pertussis toxoid and filamentous hemagglutinin), inactivated poliovirus types 1, 2, and 3, recombinant hepatitis B surface antigen (HBsAg) produced in yeast, and Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus protein (PRP-T). By combining these six pediatric immunizations into a single, fully liquid formulation, it reduces the number of injections required, simplifies vaccination schedules, and improves compliance.
- Brand names
- HexaximHexyonHexacimaHexarium
- Other names
- DTaP-IPV-HB-PRP-T vaccineDTaP-IPV-HB-Hib vaccineDTaP-HepB-IPV-Hib vaccineDTaP2-IPV-HB-Hib vaccineDTaP-2-IPV-HB-Hib vaccineDTaP 2-IPV-HB-Hib vaccineDT2aP-HBV-IPV-Hib vaccineDT-2aP-HBV-IPV-Hib vaccineDT 2aP-HBV-IPV-Hib vaccine
02
Targets
ETV6 (ETS variant transcription factor 6)Poliovirus type 3 capsid protein (PV3 capsid)HBsAg (Hepatitis B surface antigen)FHA (Filamentous hemagglutinin)Diphtheria toxin
Beyond the preview
Go deeper on DTaP-IPV-HB-PRP-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-IPV-HB-PRP-T.